Search Within

Michael John Mauro

  1. "2020"
Formats
  1. Meeting Abstract (17)
  2. Journal Article (6)
  3. Correspondence (1)
  4. Guidelines (1)
  5. Review (1)
Groups
  1. Adult Leukemia (26)
  2. Center for Hematologic Malignancies (26)
  3. Department of Medicine (26)
  4. Hematologic Malignancies, Division of (26)
  5. Breast Medicine Service (1)
  6. Center for Molecular Imaging and Biotechnology (CMIB) (1)

More Groups

People
  1. Ellin Berman (2)
  2. Ahmet Dogan (1)
  3. Allison Sigler (1)
  4. Amber King (1)
  5. Bradley Beattie (1)
  6. Daniel Danila (1)

More People

Years
  1. 2020 (26)
Publications
  1. Blood (10)
  2. Clinical Lymphoma, Myeloma and Leukemia (4)
  3. Leukemia and Lymphoma (3)
  4. Journal of Clinical Oncology (2)
  5. Arteriosclerosis Thrombosis and Vascular Biology (1)
  6. European Journal of Heart Failure (1)

More Publications

Publishers
  1. American Society of Hematology (10)
  2. Elsevier Inc. (4)
  3. Taylor & Francis Group (3)
  4. American Society of Clinical Oncology (2)
  5. Elsevier Science, Inc. (1)
  6. Lippincott Williams & Wilkins (1)

More Publishers

Results (26)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • COVID-19 in patients (pts) with chronic myeloid leukemia (CML): Results from the international CML foundation (iCMLf) CML and COVID-19 (CANDID) study
    Meeting Abstract

    Rea, D.; Mauro, M. J.; Cortes, J. E.; Jiang, Q.; Pagnano, K. B.; Ongondi, M.; Kok, C. H.; Evans, N.; Hughes, T. P.; International CML Foundation
    Blood (2020)

    Fulltext@MSK | Save
  • Impact of COVID19 pandemic on an international MPN patient population: Survey results from 1560 MPN patients
    Meeting Abstract

    Palmer, J. M.; Mead-Harvey, C.; Harrison, C.; Dueck, A. C.; Eckert, R.; Kosiorek, H. E.; Muxi, P.; Pemmaraju, N.; Arguelles, G. R.; Vannucchi, A. M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Cardiovascular and metabolic risk in patients with chronic myeloid leukemia in chronic phase receiving first-line BCR-ABL1 tyrosine kinase inhibitors in the United States: Baseline and six-month follow-up results from a prospective real-world observational study
    Meeting Abstract

    Mauro, M. J.; Oehler, V. G.; Thompson, J. E.; McCloskey, J. K.; Heinrich, M. C.; Dakhil, S. R.; DeGutis, I.; Tabano, D.; Khan, W.; Moslehi, J. J.
    Blood (2020)

    Fulltext@MSK | Save
  • Efficacy and safety of ponatinib (PON) in patients with chronic-phase chronic myeloid leukemia (CP-CML) who failed one or more second-generation (2G) tyrosine kinase inhibitors (TKIs): Analyses based on PACE and OPTIC
    Meeting Abstract

    Kantarjian, H. M.; Deininger, M. W.; Abruzzese, E.; Apperley, J.; Cortes, J. E.; Chuah, C.; DeAngelo, D. J.; DiPersio, J. F.; Hochhaus, A.; Lipton, J. H.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Phase 1 trial of vodobatinib, a novel oral BCR-ABL1 tyrosine kinase inhibitor (TKI): Activity in CML chronic phase patients failing TKI therapies including ponatinib
    Meeting Abstract

    Cortes, J. E.; Saikia, T.; Kim, D. W.; Alvarado, Y.; Nicolini, F. E.; Khattry, N.; Rathnam, K.; Apperley, J.; Deininger, M. W.; de Lavallade, H.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Outcome by mutation status and line of treatment in optic, a dose-ranging study of 3 starting doses of ponatinib in patients with CP-CML
    Meeting Abstract

    Cortes, J. E.; Apperley, J.; Hochhaus, A.; Mauro, M. J.; Rousselot, P.; Sacha, T.; Talpaz, M.; Chuah, C.; Lipton, J. H.; Deininger, M. W.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Asciminib, a first-in-class STAMP inhibitor, provides durable molecular response in patients (pts) with chronic myeloid leukemia (CML) harboring the T315I mutation: Primary efficacy and safety results from a phase 1 trial
    Meeting Abstract

    Cortes, J. E.; Hughes, T. P.; Mauro, M. J.; Hochhaus, A.; Rea, D.; Goh, Y. T.; Janssen, J.; Steegmann, J. L.; Heinrich, M. C.; Talpaz, M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Impact of comorbidities on response outcomes in patients with chronic myeloid leukemia in chronic phase treated with first-line dasatinib versus imatinib: Exploratory post hoc analysis of DASISION
    Meeting Abstract

    Breccia, M.; Mauro, M. J.; Jabbour, E.; Saglio, G.; Jimenez-Velasco, A.; le Coutre, P. D.; DeGutis, I.; Khan, W.; Sy, O.; Swanink, R.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Bosutinib (BOS) versus imatinib for newly diagnosed chronic phase (CP) chronic myeloid leukemia (CML): Final 5-year results from the BFORE trial
    Meeting Abstract

    Brümmendorf, T. H.; Cortes, J. E.; Milojkovic, D.; Gambacorti-Passerini, C.; Clark, R. E.; le Coutre, P. D.; Garcia-Gutiérrez, V.; Chuah, C.; Kota, V.; Lipton, J. H.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Efficacy and safety results from ASCEMBL, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib (BOS) in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥ 2 tyrosine kinase inhibitors (TKIs)
    Meeting Abstract

    Hochhaus, A.; Boquimpani, C.; Rea, D.; Minami, Y.; Lomaia, E.; Voloshin, S.; Turkina, A. G.; Kim, D. W.; Apperley, J.; Cortes, J. E.; more...
    Blood (2020)

    Fulltext@MSK | Save